Translational research in neurology and neuroscience 2010: Multiple sclerosis

Research output: Contribution to journalReview article

Olaf Stüve, Bernd C. Kieseier, Bernhard Hemmer, Hans Peter Hartung, Amer Awad, Elliot M. Frohman, Benjamin M. Greenberg, Michael K. Racke, Scott S. Zamvil, J. Theodore Phillips, Ralf Gold, Andrew Chan, Uwe Zettl, Ron Milo, Ellen Marder, Omar Khan, Todd N. Eagar

Over the past 2 decades, enormous progress has been made with regard to pharmacotherapies for patients with multiple sclerosis. There is perhaps no other subspecialty in neurology in which more agents have been approved that substantially alter the clinical course of a disabling disorder. Many of the pharmaceuticals that are currently approved, in clinical trials, or in preclinical development were initially evaluated in an animal model of multiple sclerosis, experimental autoimmune encephalomyelitis. Two Food and Drug Administration-approved agents (glatiramer acetate and natalizumab) were developed using the experimental autoimmune encephalomyelitis model. This model has served clinician-scientists for many decades to enable understanding the inflammatory cascade that underlies clinical disease activity and disease surrogate markers detected in patients.

Original languageEnglish (US)
Pages (from-to)1307-1315
Number of pages9
JournalArchives of neurology
Volume67
Issue number11
DOIs
StatePublished - Nov 1 2010

PMID: 20625066

PMCID: PMC3670826

Altmetrics

Cite this

Standard

Translational research in neurology and neuroscience 2010 : Multiple sclerosis. / Stüve, Olaf; Kieseier, Bernd C.; Hemmer, Bernhard; Hartung, Hans Peter; Awad, Amer; Frohman, Elliot M.; Greenberg, Benjamin M.; Racke, Michael K.; Zamvil, Scott S.; Phillips, J. Theodore; Gold, Ralf; Chan, Andrew; Zettl, Uwe; Milo, Ron; Marder, Ellen; Khan, Omar; Eagar, Todd N.

In: Archives of neurology, Vol. 67, No. 11, 01.11.2010, p. 1307-1315.

Research output: Contribution to journalReview article

Harvard

Stüve, O, Kieseier, BC, Hemmer, B, Hartung, HP, Awad, A, Frohman, EM, Greenberg, BM, Racke, MK, Zamvil, SS, Phillips, JT, Gold, R, Chan, A, Zettl, U, Milo, R, Marder, E, Khan, O & Eagar, TN 2010, 'Translational research in neurology and neuroscience 2010: Multiple sclerosis' Archives of neurology, vol. 67, no. 11, pp. 1307-1315. https://doi.org/10.1001/archneurol.2010.158

APA

Stüve, O., Kieseier, B. C., Hemmer, B., Hartung, H. P., Awad, A., Frohman, E. M., ... Eagar, T. N. (2010). Translational research in neurology and neuroscience 2010: Multiple sclerosis. Archives of neurology, 67(11), 1307-1315. https://doi.org/10.1001/archneurol.2010.158

Vancouver

Stüve O, Kieseier BC, Hemmer B, Hartung HP, Awad A, Frohman EM et al. Translational research in neurology and neuroscience 2010: Multiple sclerosis. Archives of neurology. 2010 Nov 1;67(11):1307-1315. https://doi.org/10.1001/archneurol.2010.158

Author

Stüve, Olaf ; Kieseier, Bernd C. ; Hemmer, Bernhard ; Hartung, Hans Peter ; Awad, Amer ; Frohman, Elliot M. ; Greenberg, Benjamin M. ; Racke, Michael K. ; Zamvil, Scott S. ; Phillips, J. Theodore ; Gold, Ralf ; Chan, Andrew ; Zettl, Uwe ; Milo, Ron ; Marder, Ellen ; Khan, Omar ; Eagar, Todd N. / Translational research in neurology and neuroscience 2010 : Multiple sclerosis. In: Archives of neurology. 2010 ; Vol. 67, No. 11. pp. 1307-1315.

BibTeX

@article{3f017e5615304e2592c9d938f0c94bec,
title = "Translational research in neurology and neuroscience 2010: Multiple sclerosis",
abstract = "Over the past 2 decades, enormous progress has been made with regard to pharmacotherapies for patients with multiple sclerosis. There is perhaps no other subspecialty in neurology in which more agents have been approved that substantially alter the clinical course of a disabling disorder. Many of the pharmaceuticals that are currently approved, in clinical trials, or in preclinical development were initially evaluated in an animal model of multiple sclerosis, experimental autoimmune encephalomyelitis. Two Food and Drug Administration-approved agents (glatiramer acetate and natalizumab) were developed using the experimental autoimmune encephalomyelitis model. This model has served clinician-scientists for many decades to enable understanding the inflammatory cascade that underlies clinical disease activity and disease surrogate markers detected in patients.",
author = "Olaf St{\"u}ve and Kieseier, {Bernd C.} and Bernhard Hemmer and Hartung, {Hans Peter} and Amer Awad and Frohman, {Elliot M.} and Greenberg, {Benjamin M.} and Racke, {Michael K.} and Zamvil, {Scott S.} and Phillips, {J. Theodore} and Ralf Gold and Andrew Chan and Uwe Zettl and Ron Milo and Ellen Marder and Omar Khan and Eagar, {Todd N.}",
year = "2010",
month = "11",
day = "1",
doi = "10.1001/archneurol.2010.158",
language = "English (US)",
volume = "67",
pages = "1307--1315",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "11",

}

RIS

TY - JOUR

T1 - Translational research in neurology and neuroscience 2010

T2 - Archives of Neurology

AU - Stüve, Olaf

AU - Kieseier, Bernd C.

AU - Hemmer, Bernhard

AU - Hartung, Hans Peter

AU - Awad, Amer

AU - Frohman, Elliot M.

AU - Greenberg, Benjamin M.

AU - Racke, Michael K.

AU - Zamvil, Scott S.

AU - Phillips, J. Theodore

AU - Gold, Ralf

AU - Chan, Andrew

AU - Zettl, Uwe

AU - Milo, Ron

AU - Marder, Ellen

AU - Khan, Omar

AU - Eagar, Todd N.

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Over the past 2 decades, enormous progress has been made with regard to pharmacotherapies for patients with multiple sclerosis. There is perhaps no other subspecialty in neurology in which more agents have been approved that substantially alter the clinical course of a disabling disorder. Many of the pharmaceuticals that are currently approved, in clinical trials, or in preclinical development were initially evaluated in an animal model of multiple sclerosis, experimental autoimmune encephalomyelitis. Two Food and Drug Administration-approved agents (glatiramer acetate and natalizumab) were developed using the experimental autoimmune encephalomyelitis model. This model has served clinician-scientists for many decades to enable understanding the inflammatory cascade that underlies clinical disease activity and disease surrogate markers detected in patients.

AB - Over the past 2 decades, enormous progress has been made with regard to pharmacotherapies for patients with multiple sclerosis. There is perhaps no other subspecialty in neurology in which more agents have been approved that substantially alter the clinical course of a disabling disorder. Many of the pharmaceuticals that are currently approved, in clinical trials, or in preclinical development were initially evaluated in an animal model of multiple sclerosis, experimental autoimmune encephalomyelitis. Two Food and Drug Administration-approved agents (glatiramer acetate and natalizumab) were developed using the experimental autoimmune encephalomyelitis model. This model has served clinician-scientists for many decades to enable understanding the inflammatory cascade that underlies clinical disease activity and disease surrogate markers detected in patients.

UR - http://www.scopus.com/inward/record.url?scp=77957949997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957949997&partnerID=8YFLogxK

U2 - 10.1001/archneurol.2010.158

DO - 10.1001/archneurol.2010.158

M3 - Review article

VL - 67

SP - 1307

EP - 1315

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 11

ER -

ID: 16818030